TA
Tata Nifty MidSmall Healthcare Index Fund Direct Growth
Latest NAV
+16.58% 1Y
Sign In to Add to Portfolio
Benchmark: Nifty MidSmall Healthcare Index (TRI)
Expense ratio
0.59%
AUM
₹219 Cr
Min SIP
₹100
Min lump sum
₹5,000
1Y
+16.58%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Apr 2024
Where the NAV sits & how risky it is
₹14.96
52-week range
at 82%
₹14.96
Low 23 Mar 2026₹12.03
High 23 Sep 2026₹15.62
Risk level
Very High
Low
Very high
NAV history
30 Apr 2024
Since inception
01 Oct 2026
Returns by period
1W
-3.65%
1M
-2.33%
3M
+2.27%
6M
+21.19%
1Y
+16.58%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 100.08%
Cash & other 0.27%
Sector split
Country split
Top 5 hold 38.4%
Top 10 hold 59.9%
30 equity holdings
Equity holdings
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.15%
|
+6.87% |
| 2 | Laurus Labs
INE947Q01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.82%
|
+26.89% |
| 3 | Fortis Healthcare
INE061F01013 |
Healthcare Medical Care Facilities |
India |
8.05%
|
+11.89% |
| 4 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.64%
|
+22.72% |
| 5 | Glenmark Pharmaceuticals
INE935A01035 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.70%
|
+6.94% |
| 6 | Alkem Laboratories
INE540L01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.35%
|
-1.94% |
| 7 | Biocon
INE376G01013 |
Healthcare Biotechnology |
India |
5.09%
|
+3.90% |
| 8 | Mankind Pharma
INE634S01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.47%
|
+7.33% |
| 9 | IPCA Laboratories
INE571A01038 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.52%
|
+16.24% |
| 10 | Krishna Institute of Medical Sciences
INE967H01025 |
Healthcare Medical Care Facilities |
India |
3.12%
|
+31.65% |
About this scheme
The investment objective of the scheme is to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error.
Fund manager(s): Rakesh Prajapati, Nitin Sharma
Exit load: Exit load of 0.25%, if redeemed within 15 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
26 Apr 2024
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
SBI Silver ETF FoF Direct Growth
1▲ 33.8 pts ahead of this fund
Kotak Silver ETF FoF Direct Growth
2▲ 32.9 pts ahead of this fund
Axis Silver FoF Direct Growth
3▲ 32.3 pts ahead of this fund
ICICI Prudential Strategic Metal and Energy Equity FoF Direct Growth
4▲ 32.3 pts ahead of this fund
DSP Silver ETF FoF Direct Growth
5▲ 32.1 pts ahead of this fund
Zerodha Silver ETF FoF Direct Growth
6▲ 32.1 pts ahead of this fund